Bharat Biotech’s Covaxin Found To Be Safe, Induced Immune Response In Phase-1: Data

New Delhi: Bharat Biotech’s coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet, MoneyControl reported.

In Phase-1, potential vaccines are tested on healthy human volunteers to check for the safety or potential side-effects of the vaccine and the immunogenicity, or the immune response that enables the body to fight an infection.

Covaxin has been developed by the Hyderabad-based biotechnology firm in collaboration with the Indian Council of Medical Research and the National Institute of Virology. The vaccine is now undergoing phase-3 trials. Phase 2 trials are being analysed.

Other facts

  • Bharat Biotech conducted the Phase-1 study between July 13 and 30, 2020.
  • The company said it screened 897 individuals but ended up enrolling 375.
  • The participants were between 18 and 55 years of age.
  • The duration of the study is 12 months.
  • All the participants will be followed-up during this period.

The most common adverse event was pain at the injection site followed by headache, fatigue, and fever, the study said, according to MoneyControl.


Get real time updates directly on you device, subscribe now.

Comments are closed.